-
Something wrong with this record ?
Navigating the introduction of anti-amyloid therapy in Europe: a position statement by individual members of the EADC
KS. Frederiksen, M. Boada, B. Dubois, S. Engelborghs, GB. Frisoni, J. Georges, J. Hort, L. Jönsson, MG. Kramberger, PJ. Ousset, N. Scarmeas, R. Schmidt, JM. Schott, L. Spiro, G. Waldemar, B. Winblad, F. Jessen, L. Frölich
Language English Country England, Great Britain
Document type Journal Article, Review
NLK
BioMedCentral
from 2009-06-01
BioMedCentral Open Access
from 2009
Directory of Open Access Journals
from 2009
Free Medical Journals
from 2009
PubMed Central
from 2009
ProQuest Central
from 2015-01-01
Open Access Digital Library
from 2009-01-01
Open Access Digital Library
from 2009-01-01
Health & Medicine (ProQuest)
from 2015-01-01
ROAD: Directory of Open Access Scholarly Resources
from 2009
Springer Nature OA/Free Journals
from 2009-06-01
- MeSH
- Alzheimer Disease * drug therapy therapy MeSH
- Amyloid beta-Peptides * immunology MeSH
- Humans MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Review MeSH
- Geographicals
- Europe MeSH
INTRODUCTION: Anti-amyloid antibodies for the treatment of Alzheimer ́s disease (AD) are currently being evaluated for approval and reimbursement in Europe. An approval brings opportunities, but also challenges to health care systems across Europe. The objective of this position paper is to provide guidance from experts in the field in terms of navigating implementation. METHODS: Members of the European Alzheimer's Disease Consortium and a representative of Alzheimer Europe convened to formulate recommendations covering key areas related to the possible implementation of anti-amyloid antibodies in AD through online discussions and 2 rounds of online voting with an 80% threshold for a position to be accepted. RESULTS: In total, 24 recommendations were developed covering the research landscape and priorities within research in AD following a possible approval, potential impact on health care systems and diagnostic pathways, and communication to patients about anti-amyloid antibodies. Anti-amyloid antibodies are regarded as a substantial innovation with an important clinical impact. In addition, however, new compounds with other mechanisms of action and/or route of administration are also needed. Approval of new treatments will require changes to existing patient pathways and real-world data needs to be generated. CONCLUSION: Comprehensive guidance is provided on the potential implementation of anti-amyloid antibody therapies in Europe following possible approval. Emphasis is placed on the necessity of regularly updating recommendations as new evidence emerges in the coming years.
Ace Alzheimer Center Barcelona Universitat Internacional de Catalunya Barcelona Spain
Aging and Inflammation Theme Karolinska University Hospital Stockholm Sweden
Alzheimer Europe Luxembourg Luxembourg
Carol Davila University of Medicine and Pharmacy Bucharest Romania
Clinical Division of Neurogeriatrics Department of Neurology Medical University Graz Graz Austria
Dementia Research Centre UCL Queen Square Institute of Neurology UCL London UK
Department of Biomedical Sciences University of Antwerp Antwerp Belgium
Department of Neurology and Bru BRAIN NEUR Research Group Center for Neurosciences Brussels Belgium
Department of Psychiatry Medical Faculty University of Cologne Cologne Germany
Faculty Geneva College of Longevity Science Geneva Switzerland
Frontlab Paris Brain Institute AP HP Pitié Salpêtrière Hospital Paris France
German Center for Neurodegenerative Diseases Bonn Germany
Networking Research Center On Neurodegenerative Diseases Instituto de Salud Carlos 3 Madrid Spain
Toulouse Clinical Research Center Toulouse University Hospital Toulouse France
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25015669
- 003
- CZ-PrNML
- 005
- 20250731091148.0
- 007
- ta
- 008
- 250708s2025 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1186/s13195-025-01766-y $2 doi
- 035 __
- $a (PubMed)40413561
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Frederiksen, Kristian S $u Danish Dementia Research Centre, Department of Neurology, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark. Kristian.steen.frederiksen@regionh.dk $u Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. Kristian.steen.frederiksen@regionh.dk
- 245 10
- $a Navigating the introduction of anti-amyloid therapy in Europe: a position statement by individual members of the EADC / $c KS. Frederiksen, M. Boada, B. Dubois, S. Engelborghs, GB. Frisoni, J. Georges, J. Hort, L. Jönsson, MG. Kramberger, PJ. Ousset, N. Scarmeas, R. Schmidt, JM. Schott, L. Spiro, G. Waldemar, B. Winblad, F. Jessen, L. Frölich
- 520 9_
- $a INTRODUCTION: Anti-amyloid antibodies for the treatment of Alzheimer ́s disease (AD) are currently being evaluated for approval and reimbursement in Europe. An approval brings opportunities, but also challenges to health care systems across Europe. The objective of this position paper is to provide guidance from experts in the field in terms of navigating implementation. METHODS: Members of the European Alzheimer's Disease Consortium and a representative of Alzheimer Europe convened to formulate recommendations covering key areas related to the possible implementation of anti-amyloid antibodies in AD through online discussions and 2 rounds of online voting with an 80% threshold for a position to be accepted. RESULTS: In total, 24 recommendations were developed covering the research landscape and priorities within research in AD following a possible approval, potential impact on health care systems and diagnostic pathways, and communication to patients about anti-amyloid antibodies. Anti-amyloid antibodies are regarded as a substantial innovation with an important clinical impact. In addition, however, new compounds with other mechanisms of action and/or route of administration are also needed. Approval of new treatments will require changes to existing patient pathways and real-world data needs to be generated. CONCLUSION: Comprehensive guidance is provided on the potential implementation of anti-amyloid antibody therapies in Europe following possible approval. Emphasis is placed on the necessity of regularly updating recommendations as new evidence emerges in the coming years.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a Alzheimerova nemoc $x farmakoterapie $x terapie $7 D000544
- 650 12
- $a amyloidní beta-protein $x imunologie $7 D016229
- 651 _2
- $a Evropa $7 D005060
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Boada, Mercé $u Ace Alzheimer Center Barcelona - Universitat Internacional de Catalunya, Barcelona, Spain $u Networking Research Center On Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain
- 700 1_
- $a Dubois, Bruno $u Institute of Memory and Alzheimer's Disease (IM2 A), Department of Neurology, Assistance Publique-Hôpitaux de Paris (AP-HP), Sorbonne University, Pitié-Salpêtrière Hospital, Paris, France $u Frontlab, Paris Brain Institute (Institut du Cerveau, ICM), AP-HP, Pitié-Salpêtrière Hospital, Paris, France
- 700 1_
- $a Engelborghs, Sebastiaan $u Department of Neurology and Bru-BRAIN, NEUR Research Group, Center for Neurosciences (C4 N), Universitair Ziekenhuis Brusseland, VrijeUniversiteit Brussel (VUB) , Brussels, Belgium $u Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium
- 700 1_
- $a Frisoni, Giovanni B $u LANVIE - Laboratory of Neuroimaging of Aging, Memory Centerand, University Hospitals and University of Geneva , Geneva, Switzerland
- 700 1_
- $a Georges, Jean $u Alzheimer Europe, Luxembourg, Luxembourg
- 700 1_
- $a Hort, Jakub $u Department of Neurology, Second Faculty of Medicine, Memory Clinic, Charles University and Motol University Hospital, Prague, Czech Republic
- 700 1_
- $a Jönsson, Linus $u Division of Neurogeriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Solna, Sweden
- 700 1_
- $a Kramberger, Milica G $u Department of Neurology, Faculty of Medicine, University Medical Center, University of Ljubljana, Ljubljana, Slovenia $u Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden
- 700 1_
- $a Ousset, Pierre-Jean $u Toulouse Clinical Research Center, Toulouse University Hospital, Toulouse, France
- 700 1_
- $a Scarmeas, Nikolaos $u 1, Department of Neurology, Aiginition Hospital, National and Kapodistrian University of Athens Medical School GR, Athens, Greece $u Department of Neurology, Taub Institute for Research in Alzheimer's Disease and the Aging Brain, The Gertrude H. Sergievsky Center, Columbia University, New York, NY, USA
- 700 1_
- $a Schmidt, Reinhold $u Clinical Division of Neurogeriatrics, Department of Neurology, Medical University Graz, Graz, Austria
- 700 1_
- $a Schott, Jonathan M $u Dementia Research Centre, UCL Queen Square Institute of Neurology, UCL, London, UK
- 700 1_
- $a Spiro, Luiza $u Carol Davila" University of Medicine and Pharmacy (www.umfcd.ro), Bucharest, Romania $u Faculty, Geneva College of Longevity Science (www.gcls.study), Geneva, Switzerland $u Faculty, Geneva School of Business Administration, University of Applied Sciences of Western Switzerland (www.hesge.ch), Geneva, Switzerland $u President "Ana ASLAN International" Foundation (www.anaaslanacademy.ro), Excellence Memory Center, Brain Health, and Longevity Medicine, Bucharest, Romania
- 700 1_
- $a Waldemar, Gunhild $u Danish Dementia Research Centre, Department of Neurology, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark $u Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
- 700 1_
- $a Winblad, Bengt $u Aging and Inflammation Theme, Karolinska University Hospital, Stockholm, Sweden $u Division of Neurogeriatrics, Dept of Neurobiology, Care Sciences and Society, Theme Inflammation & Aging, Karolinska Institutet, Karolinska University Hospital, Huddinge, Sweden
- 700 1_
- $a Jessen, Frank $u Department of Psychiatry, Medical Faculty, University of Cologne, Cologne, Germany $u German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany $u Excellence Cluster On Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany
- 700 1_
- $a Frölich, Lutz $u Department of Geriatric Psychiatry, Medical Faculty Mannheim, Central Institute of Mental Health, Heidelberg University, Mannheim, Germany
- 773 0_
- $w MED00172451 $t Alzheimer's research & therapy $x 1758-9193 $g Roč. 17, č. 1 (2025), s. 116
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/40413561 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250708 $b ABA008
- 991 __
- $a 20250731091142 $b ABA008
- 999 __
- $a ok $b bmc $g 2366494 $s 1252794
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2025 $b 17 $c 1 $d 116 $e 20250524 $i 1758-9193 $m Alzheimer's research & therapy $n Alzheimers Res Ther $x MED00172451
- LZP __
- $a Pubmed-20250708
